RT Journal Article
SR Electronic
T1 Patients at risk of pulmonary fibrosis Post Covid-19: Epidemiology, pulmonary sequelaes and humoral response
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.04.22271920
DO 10.1101/2022.03.04.22271920
A1 Porto, Miriam Hernández
A1 Delgado, Teresa
A1 Aguirre-Jaime, Armando
A1 Ramos, María Jose
A1 Campos, Silvia
A1 Acosta, Orlando
A1 Llanos, Ana Belén
A1 Lecuona, María
YR 2022
UL http://medrxiv.org/content/early/2022/03/07/2022.03.04.22271920.abstract
AB Background The COVID-19 pandemic is one of the greatest public health problems. Our aims were to describe epidemiological characteristics, know the amount of protective antibodies and their permanence after a COVID-19 primary infection in patients with risk of pulmonary fibrosis.Methods Descriptive epidemiological and follow-up study of the humoral response in patients at risk of pulmonary fibrosis Post-Covid-19 hospitalized, between March and October 2020, and who were followed up for a one year after hospital discharge.Results 72 patients participated in the study, 52 showed pre-existing chronic comorbidities. COVID-19 clinical severity was rated in 6% mild, 58% as moderate and 36% as severe. After a year of follow-up, the forty percent had pulmonary sequelae, the most frequent (20%) was mild pulmonary fibrosis. Any case of reinfection was detected. All patients presented RBD IgG antibodies and 88% presented IgA antibodies after 8-9 months. The amount of RBD IgG was similar at 4-5 and 8-9 months post-Covid. There was no difference when level of RBD IgG according to the severity of the COVID-19 (p=0.441, p=0.594).Conclusions Mild pulmonary fibrosis sequelae is exceptional but was detected in a high percentage. The amount of RBD IgG is maintained throughout the convalescent phase and seems to protect against new reinfections despite of emerging viral variants. However, seems not predict the developed or not of pulmonary fibrosis.Competing Interest StatementThe authors have declared no competing interest.Funding Statementyes Funded study MHP This work is supported by the PIFIISC20/36 grant of the FundaciÃ3n Canaria Instituto de InvestigaciÃ3n Sanitaria de Canarias (FIISC). www.fciisc.org The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hospital Universitario de Canarias. The study was approved by Ethical Committee with the code CHUC_2020_68.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.